Hengrui inks licensing deal with GSK
Hengrui Pharmaceuticals has licensed global rights to its HRS-9821 program and granted GSK options on up to 11 additional candidates, excluding Greater China. GSK will pay USD 500 million upfront, with milestone payments tied to development, registration, and sales potentially totaling up to USD 12 billion.